Skip to main content
main-content

01.03.2012 | Short Communication | Ausgabe 3/2012 Open Access

Supportive Care in Cancer 3/2012

Thyroid cancer patients’ involvement in adjuvant radioactive iodine treatment decision-making and decision regret: an exploratory study

Zeitschrift:
Supportive Care in Cancer > Ausgabe 3/2012
Autoren:
A. M. Sawka, S. Straus, A. Gafni, S. Meiyappan, D. David, G. Rodin, J. D. Brierley, R. W. Tsang, L. Thabane, L. Rotstein, S. Ezzat, D. P. Goldstein

Abstract

Purpose

We explored regret in thyroid cancer patients, relating to the decision to accept or reject adjuvant radioactive iodine treatment.

Methods

We studied patients with a recent diagnosis of early stage papillary thyroid carcinoma, in whom treatment decisions on adjuvant radioactive iodine had been finalized. Participants completed a Decision Regret Scale questionnaire. We asked the participants to identify who made the final decision about radioactive iodine treatment. We explored the relationship between decision regret and a) degree of patient involvement in decision-making and b) receipt of radioactive iodine treatment.

Results

We included 44 individuals, more than half of whom received adjuvant radioactive iodine treatment (26/44). Decision regret was generally low (mean 22.1, standard deviation [SD] 13.0). Participants reported that the final treatment decision was made by the following: patient and doctor (52.3%, 23/44), completely the patient (27.3%, 12/44), or completely the physician (20.5%, 9/44). Decision regret significantly differed according to who made the final decision: the patient (mean 19.0, SD 11.3), patient and doctor (mean 19.5, SD 7.4), and the doctor (mean 32.9, SD 20.37) (F = 4.569; degrees of freedom = 2, 41; p = 0.016). There was no significant difference in decision regret between patients who received radioactive iodine and those who did not (mean difference −2.5; 95% confidence interval −10.6, 5.6; p = 0.540).

Conclusion

Thyroid cancer patients who reported being involved in the final treatment decision on adjuvant radioactive iodine had less regret than those who did not.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Onkologie

Kombi-Abonnement

Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl. 

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2012

Supportive Care in Cancer 3/2012 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise